Treatment of autoimmune disease with extracorporeal photochemotherapy: pemphigus vulgaris--preliminary report. by Rook, A. H. et al.
THE YALE JOURNAL OF BIOLOGY AND MEDICINE 62 (1989), 647-652
Treatment ofAutoimmune Disease with Extracorporeal
Photochemotherapy: Pemphigus Vulgaris
Preliminary Report
ALAIN H. ROOK, M.D., PETER W. HEALD, M.D.,
GEORGE T. NAHASS, M.D., WILLIAM MACEY, R.N.,
WILLIAM K. WITMER, M.D., GERALD S. LAZARUS, M.D.,
AND BRIAN V. JEGASOTHY, M.D.
General Clinical Research Center, Hospital ofthe University ofPennsylvania,
Philadelphia, Pennsylvania, and Departments ofDermatology, Hospital ofthe
University ofPennsylvania, Philadelphia, and Yale University School ofMedicine,
New Haven, Connecticut
Received July 18, 1989
Extracorporeal photochemotherapy is a new form of immunotherapy which involves the
extracorporeal photoinactivation of peripheral blood cells by 8-methoxypsoralen in the presence
of ultraviolet A irradiation, followed by readministration of the cells. To explore the efficacy of
this therapy in the treatment of autoimmune disease, four patients with a lengthy history of
corticosteroid and immunosuppressive drug-resistant pemphigus vulgaris were initiated on
extracorporeal photochemotherapy. Three patients experienced a complete remission in cuta-
neous disease expression, permitting discontinuation of medications in two and a substantial
decrease in the third. Significant reductions in serum antiepidermal cell antibody titers occurred
in all four patients. The treatments were well tolerated without the occurrence ofadverse events.
These results in a small number of patients suggest that extracorporeal photochemotherapy may
prove to be a useful tool in the treatment ofaggressive autoimmune disease.
Pemphigus vulgaris is an autoimmune blistering disease that involves the mucosal
[ I and cutaneous surfaces. It is characterized by the presenceofserum immunoglobu-
lin G antibodies against a 130 kilodalton protein within the epidermis [2]. During the
early course ofthe disease, many patients experience the formation ofintraoral ulcers.
This condition is usually followed by the occurrence of flaccid cutaneous blisters,
which easily rupture to leave superficial erosions [I]. Prior to the era ofcorticosteroid
use, more than 80 percent of patients with pemphigus vulgaris died as a result of
complications of their disease [3]. Although the current use of steroids and immuno-
suppressive drugs simplifies the management of patients with pemphigus vulgaris,
disease control often requires excessive doses of these medications, with the inevitable
occurrence of drug-related complications, including life-threatening infections, osteo-
porosis, diabetes mellitus, and hypertension. Moreover, frequent disease relapses often
necessitate the chronic use of these medications.
Extracorporeal photochemotherapy is a new form ofimmunotherapy, which permits
the extracorporeal exposure of pathogenic peripheral blood leukocytes to the natural
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CLPHOTOPHERESIS FOR PEMPHIGUS VULGARIS
compound 8-methoxypsoralen (8-MOP) and ultraviolet A radiation. This therapy has
recently been demonstrated to provide substantial clinical benefit for certain advanced
forms of cutaneous T-cell lymphoma [4]. At our institutions, we have observed an
unprecedented number of sustained complete remissions of the Sezary form of
cutaneous T-cell lymphoma in patients who were treated with extracorporeal photo-
chemotherapy. In this report, we describe our satisfactory experience with the use of
extracorporeal photochemotherapy in the treatment of four patients with chronic
pemphigus vulgaris who had previously required large doses of immunosuppressive
drugs to control the disabling effects of their disease.
PATIENTS
Four patients with a biopsy-confirmed diagnosis of pemphigus vulgaris (two from
Yale University School of Medicine and two from the Hospital of the University of
Pennsylvania) were treated with extracorporeal photochemotherapy under protocols
approved by the respective institutional review boards. Patient characteristics, includ-
ing disease duration, extent ofclinical involvement, and drug treatment at the time of
initiation of extracorporeal photochemotherapy, are listed in Table 1. Prior to starting
extracorporeal photochemotherapy, cutaneous lesions from all patients were evaluated
by hematoxylin and eosin staining for the presence of suprabasilar epidermolysis and
by direct immunofluorescence for the presence of immunoglobulin in the intercellular
spaces ofthe epidermis. At baseline and at three-month intervals, assessment ofserum
levels of antiepidermal cell antibodies was performed by indirect immunofluores-
cence.
TREATMENT PROCEDURE
The treatment of the patients was accomplished using the UVAR photopheresis
system (Therakos, West Chester, PA) in a manner similar to that which has been
previously described for cutaneous T-cell lymphoma [4]. Briefly, two hours following
the ingestion of 0.6 mg of 8-MOP per kilogram of body weight, patients underwent a
discontinuous leukapheresis procedure with subsequent exposure of removed leuko-
cytes to ultraviolet A radiation. During the procedure, approximately 240 ml of
leukocyte-enriched blood was mixed with 300 ml ofthe patient's plasma and 200 ml of
sterile normal saline. The final buffy coat preparation contained an estimated 25-50
percent of the total peripheral blood leukocyte compartment and had a hematocrit
ranging from 2.5 to 8 percent. The buffy coat then passed as a 1 mm film through a
sterile cassette, permitting a 270-minute exposure to ultraviolet A, yielding an average
exposure per lymphocyte of 2 J/cm2. Following exposure of the cells to ultraviolet A,
the buffy coat is returned to the patient. During the initial phases of therapy, patients
received the treatment on each of two successive days at four-week intervals. If, after
three treatments, improvement was not observed, therapy was increased to two
treatments on successive days at two- to three-week intervals.
CASE HISTORIES
Patient I
Patient I was a 61-year-old male with a four-year history of pemphigus vulgaris. At
the time of referral for extracorporeal photochemotherapy, he had on his face, scalp,
neck, and trunk extensive blisters and erosions, which had been resistant to many
months of therapy with doses of prednisone and azathioprine as high as 100 mg and
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150 mg, respectively. His serum antiepidermal cell antibody titer had ranged from 1:80
to 1:640. Extracorporeal photochemotherapy was initiated with treatments on two
consecutive days every three weeks. By the third cycle of treatment, new blister
formation had ceased, and by the fourth cycle prednisone and azathioprine had been
tapered to 20 mg and 50 mg, respectively. At the seventh cycle, treatment frequency
was reduced to every five weeks. Two months subsequently, numerous new skin lesions
appeared, coincident with a fourfold rise in serum antiepidermal cell antibody titer.
Extracorporeal photochemotherapy treatments were administered every two weeks,
with suppression of new lesion formation and clearing of erosions. The antibody titer
dropped from 1:1,280 to 1:40 over a three-month period. During the next seven
months, while treatments were maintained every two to three weeks, one to three new
blisters occurred between treatments. The time between treatment cycles was again
extended to four weeks, and prednisone was decreased to 10 mg daily, while
azathioprine remained at 50 mg daily. Within two months, numerous new lesions were
noted, and the patient elected to discontinue extracorporeal photochemotherapy
(month 24, Table 1).
Prednisone was increased from 10 mg daily to 80 mg daily during the next month,
and cyclophosphamide at a dose of 2 mg/kg daily was added. Despite continuing this
therapy for six months, more than 50 percent ofthe body surface area became involved
with numerous large erosions (Fig. IA). The antiepidermal cell antibody titer rose to
1:2,560. Cyclophosphamide was discontinued, and extracorporeal photochemotherapy
treatments were reinstituted, with four treatments administered over eight days,
followed by treatment cycles every three weeks. By the second three-week cycle, no
new lesions had appeared, and by the third three-week cycle, all skin erosions had
healed (Fig. I B), and the antibody titer had dropped to 1:80.
Patient 2
Patient 2 was a 78-year-old female with a three-year history of pemphigus vulgaris,
manifesting as recurrent blisters and erosions on her face, trunk, and oral mucosa.
From 1979 to 1982, prednisone in doses ranging from 60-100 mg daily was necessary
to prevent new lesion formation. During the use of prednisone, hypertension and
diabetes mellitus occurred, and bilateral cataract formation was observed. The serum
antiepidermal cell antibody titer fluctuated between 1:80 and 1:640. In November
1982, extracorporeal photochemotherapy treatments were initiated, with two consecu-
tive daily treatments administered every two to four weeks (Fig. IC). At this time,
repetitive examination of peripheral blood lymphocyte phenotypes revealed an absence
of suppressor (CD8+) T cells with100 percent of cells staining with CD4 (helper T
cells). By February 1983, new lesions had ceased appearing and progressive healing
was noted. By August 1983, the skin had cleared completely, while the serum
antiepidermal cell antibody titer had dropped from1:1,280 to an undetectable level.
Levels of CD8+ T cells were noted to increase to 34 percent of the peripheral blood
lymphocyte compartment. By September 1983, prednisone had been discontinued
completely. Extracorporeal photochemotherapy treatments were provided every four
to five weeks until June 1984, when treatments were discontinued in the absence of
clinical disease and an undetectable serum antiepidermal cell antibody titer. In
September 1984, a mild disease flare occurred in association with a fall in CD8 + cells
to10 percent. She again responded to resumption of extracorporeal photochemother-
apy treatments every two to three weeks with a rise in CD8 + cells to 24 percent. The
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FIG. I. A. Patient I at month 26 (offextracorporeal photochemotherapy). B. Patient I at month 30,
following aggressive resumption ofextracorporeal photochemotherapy. C. Patient 2, prior to initiation
ofextracorporeal photochemotherapy. D. Patient 2, demonstrating a complete response to treatment.
patient has been off all therapy since 1986 without evidence of skin lesions and with
undetectable serum antiepidermal antibodies (Fig. 1D).
DISCUSSION
As demonstrated by the case reports and the clinical data in Table 1, all four
patients with chronic drug-resistant pemphigus vulgaris treated in this pilot study
experienced clinical improvement during the initial phases of the protocol employing
extracorporeal photochemotherapy. In parallel, all four experienced significant
decreases in their serum antiepidermal cell antibody titers. Three patients had
prolonged remissions, which permitted reductions in glucocorticoid and immunosup-
pressive medications to trivial amounts. Moreover, patients 2 and 3 have been able to
terminate all therapy during a four-year and a one-year period, respectively, during
which they have been in complete remission.
The time course for the induction of a beneficial therapeutic response to extracor-
poreal photochemotherapy was variable. In the case of patient 1, an aggressive
regimen, consisting of four treatments over an eight-day period, appears to have been
responsible for the rapid reinduction of a clinical remission over just a three-week
period, which had not been previously possible with high doses of cyclophosphamide
and prednisone. In our experience, weekly or biweekly treatments will suppress disease
activity in those patients exhibiting accelerated progression ofclinical symptoms, while
maintenance therapy provided every three to four weeks is generally satisfactory for
sustaining an improved clinical response. In this regard, it is noteworthy that patient 4,
who initially improved when treated with extracorporeal photochemotherapy, but who
651652 ROOK ET AL.
now continues to develop new vesicles, has not received an aggressive course oftherapy
comparable to that of patient 1. We are expecting to undertake such a course of
therapy in the future.
At present, the useofcorticosteroids and immunosuppressive drugs is responsible for
inducing clinical remissions in the majority of patients with pemphigus vulgaris. The
mortality remains at 5-15 percent ofcases, however, largely due to the complications
ofthese potent immune-suppressing medications. It should be emphasized that the use
ofextracorporeal photochemotherapy permitted reductions in drug dosage in all ofour
patients. Although the precise therapeutic mechanism of extracorporeal photochemo-
therapy is currently unknown, the observation that none ofour patients exhibited signs
of immune deficiency, such as enhanced susceptibility to infection, despite many
months oftherapy, strongly suggests that extracorporeal photochemotherapy mediates
its beneficial effect by means other than blunting of the immune response. In fact,
recent evidence from an experimental murine system suggests that 8-MOP and
ultraviolet A treatment of autoreactive T cells followed by the reintroduction of these
cells can lead to a clone-specific immune response which may down-regulate the
activity of the pathogenic T cells [5]. Moreover, our data on patient 2 indicate that an
immunoregulatory imbalance in suppressor T cells may be favorably altered by
extracorporeal photochemotherapy treatments. A correction of this imbalance in
response to treatment may be relevant to the decrease in production of antibodies
observed in all ofour patients.
Thus, we have demonstrated that extracorporeal photochemotherapy appears to be
a well-tolerated alternative form of therapy for patients with aggressive cases of
pemphigus vulgaris that fail to respond to high doses of immunosuppressive medica-
tions. This treatment has produced a remarkable corticosteroid-sparing effect while
inducing clinical remissions in three offour patients. We anticipate that future clinical
trials may reveal the usefulness of this new form of therapy for other autoimmune
diseases.
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